- Male breast cancer (MBCa) is associated with worse OS than female BCa (FBCa) at stages I and II, and similar OS at stages III and IV.
- Hormone receptor-positive/human epidermal growth factor receptor 2-positive (HR+/HER2+) disease was associated with doubled mortality risk in men vs women.
Why this matters
- MBCa, which is increasing in incidence, may warrant more aggressive treatment at stages I and II.
- Population-based retrospective cohort of 1187 patients with MBCa and patients with 166,054 FBCa with known HR/HER2 status in the Surveillance, Epidemiology, and End Results (SEER) database.
- Funding: None disclosed.
- Median follow-up was 21 months (range, 1-48 months).
- MBCa had worse OS (85.6% vs 90.4% for FBCa; P=.0002).
- Effect driven by worse OS at stage I (HR, 1.99; 95% CI, 1.2-3.3) and stage II (HR, 1.5; 95% CI, 1.1-2.2).
- No OS differences at stage III and IV.
- MBCa was more likely than FBCa to be ductal, have a higher grade, present at a more advanced stage, and more often be HR+/HER2− (each P<.0001>
- On multivariate analysis, no OS gender differences by subtype, except for HR+/HER2+ showing worse survival in men (HR, 2.091; P=.002).
- Short follow-up.